What is HC Wainwright’s Forecast for ZNTL Q3 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Friday, November 15th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.67) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.76) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q4 2025 earnings at ($0.68) EPS.

A number of other equities analysts have also commented on ZNTL. Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective on the stock in a report on Monday, August 12th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Finally, Guggenheim lowered their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

Zentalis Pharmaceuticals Trading Down 12.1 %

NASDAQ ZNTL opened at $3.05 on Monday. The stock has a market cap of $217.34 million, a P/E ratio of -1.22 and a beta of 1.74. The company’s fifty day simple moving average is $3.42 and its 200-day simple moving average is $5.33. Zentalis Pharmaceuticals has a 52 week low of $2.66 and a 52 week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. ProShare Advisors LLC lifted its stake in Zentalis Pharmaceuticals by 9.0% during the first quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock worth $243,000 after purchasing an additional 1,274 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Zentalis Pharmaceuticals by 20.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after buying an additional 585,644 shares during the last quarter. Kennedy Capital Management LLC bought a new stake in shares of Zentalis Pharmaceuticals during the 1st quarter valued at about $189,000. Opaleye Management Inc. acquired a new stake in Zentalis Pharmaceuticals during the first quarter worth about $3,152,000. Finally, SG Americas Securities LLC bought a new position in Zentalis Pharmaceuticals in the second quarter worth about $58,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.